Te‐Chun Hsia
China Medical University(TW)China Medical University Hospital(TW)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment, Colorectal Cancer Treatments and Studies, Bioactive Compounds and Antitumor Agents
Most-Cited Works
- → Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial(2012)402 cited
- → Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy(2019)399 cited
- → Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial(2020)251 cited
- → Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations(2015)244 cited
- → Chrysophanol induces necrosis through the production of ROS and alteration of ATP levels in J5 human liver cancer cells(2010)208 cited
- → Danthron, an Anthraquinone Derivative, Induces DNA Damage and Caspase Cascades-Mediated Apoptosis in SNU-1 Human Gastric Cancer Cells through Mitochondrial Permeability Transition Pores and Bax-Triggered Pathways